The Readout Loud 324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug
Sep 26, 2024
Jonathan Wosen, a seasoned colleague in oncology research, shares insights on the latest shifts in the life sciences. The conversation highlights Genentech's decision to close its cancer immunology division and the reaction from the biotech community. Wosen also discusses Pfizer’s withdrawal of its sickle cell treatment and the implications for future drug approvals. Additionally, they explore the promising prospects of a new schizophrenia drug set to be approved, emphasizing the urgent need for innovative therapies in mental health.
AI Snips
Chapters
Transcript
Episode notes
Genentech Cancer Immuno Closure
- Genentech closed its cancer immunology group after many years of notable contributions, disappointing some employees.
- The group was behind breakthroughs like Tecentriq but struggled with new targets beyond initial successes.
Keytruda's Dominance in Immunotherapy
- It has been very challenging for biotech to replicate Keytruda's success in cancer immunotherapy.
- Keytruda set a very high bar with 40 indications and proven survival benefits, making it tough to match.
AI's Impact on Genentech R&D Staff
- Some Genentech scientists worry AI's growing role in research may reduce demand for traditional bench researchers.
- Layoffs have stirred concerns about a shifting R&D focus toward AI-driven discovery.